Our Story

A passion for biopharmaceutical innovation

What happens when you bring together a team of renowned scientific leaders with a history of pioneering innovations and an ambitious vision? At PharmaEssentia, it leads to exciting innovations, rapid growth, and the potential to make a real impact for patients with rare hematologic cancers.

Guided by a powerful vision

PharmaEssentia was created in 2003 to realize a compelling vision: Bring together leading scientists from the U.S., Taiwan and beyond to challenge the status quo for treatment of rare hematologic cancers. Led by Dr. Ko-Chung Lin, a scientist with experience leading pioneering work for Biogen®, our founders embarked on an ambitious plan to rethink interferon-based treatment opportunities. With enthusiastic support from the Taiwanese government and private investors, PharmaEssentia was born.

A global expansion strategy

Today, guided by the vision of CEO Ko-Chung Lin and Chairperson Ching-Leou Teng, PharmaEssentia has grown to become a leader in the development and production of novel therapies. With hundreds of employees worldwide, including a growing presence in the U.S., PharmaEssentia is a publicly traded company (6446.TWO) with a rich pipeline. The company has fully integrated capabilities, including R&D and cGMP production facilities in Taiwan.

A culture of excellence

At PharmaEssentia, we believe true innovation lies in balancing rich science and inspired thinking. That’s why we encourage intellectual curiosity and a commitment to rigorous research. While we are passionate about innovation, we never lose sight of our goal: to create new treatment opportunities for underserved patient communities.